Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers-Reference-Cited by-同舟云学术

Elevated levels of cerebrospinal fluid Î±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers

Published:2014-09-25 Issue: Volume:6 Page:
ISSN:1663-4365
Container-title:Frontiers in Aging Neuroscience
language:
Short-container-title:Front. Aging Neurosci.

Author:

Aasly Jan O.,Johansen Krisztina K.,BrÃ¸nstad Gunnar,WarÃ¸ BjÃ¸rg J.,Majbour Nour K.,Varghese Shiji,Alzahmi Fatimah,Paleologou Katerina E.,Amer Dena A. M.,Al-Hayani Abdulmonem,El-Agnaf Omar M. A.

Publisher

Frontiers Media SA

Subject

Cognitive Neuroscience,Aging

Reference35 articles.

1. Clinical features of LRRK2-associated Parkinsonâ€™s disease in central Norway;Aasly;Ann. Neurol.,2005

2. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinsonâ€™s disease;Aasly;Mov. Disord.,2010

3. LRRK2 and Parkinson disease;DÃ¤chsel;Arch. Neurol.,2010

4. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinsonâ€™s disease;Di Fonzo;Lancet,2005

5. Alpha-synuclein implicated in Parkinsonâ€™s disease is present in extracellular biological fluids, including human plasma;El-Agnaf;FASEB J.,2003

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Diagnostic Potential of Combined Salivary and Skin Biomarkers in Parkinson’s Disease;International Journal of Molecular Sciences;2024-04-28

2. Comparison of biospecimens for α‐synuclein seed amplification assays in Parkinson's disease: A systematic review and network meta‐analysis;European Journal of Neurology;2023-08-28

3. α-synuclein as a promising biomarker for developing diagnostic tools against neurodegenerative synucleionopathy disorders;TrAC Trends in Analytical Chemistry;2023-02

4. Comparison of Different Biospecimens for α-Synuclein Seed Amplification Assays in Parkinson's Disease: A Systematic Review and Network Meta-Analysis;2023

5. Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers;Movement Disorders;2022-10-17